Sermorelin

Sermorelin is presented as a GHRH analog that activates GHRH receptors on pituitary somatotrophs to trigger endogenous growth hormone release in pulses. The protocol emphasizes that this approach differs from administering growth hormone directly: because secretion is stimulated physiologically, the normal regulatory system remains active. Somatostatin and IGF-1 provide negative feedback, which helps prevent sustained supraphysiologic hormone levels. The GH pulses induced by sermorelin promote downstream IGF-1 production and are associated in the protocol with anabolic and recovery-related processes, including protein synthesis and lipolysis signaling. Pediatric research cited on the page shows improvements in growth velocity in GH-deficient children with nightly administration. For adults, the protocol notes that evidence is more limited and typically extrapolated, and that effectiveness requires a functional pituitary; it will not work when pituitary damage or primary GH gene defects prevent normal GH production.